Arena Stock Hits New 52-Week Low (ARNA)

NEW YORK ( TheStreet) -- Arena Pharmaceuticals (Nasdaq: ARNA) hit a new 52-week low Friday as it is currently trading at $6.91, below its previous 52-week low of $6.95 with 2.1 million shares traded as of 9:56 a.m. ET. Average volume has been 5.7 million shares over the past 30 days.

Arena has a market cap of $1.61 billion and is part of the health care sector and drugs industry. Shares are down 17.8% year to date as of the close of trading on Wednesday.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Arena as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. You can view the full Arena Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says